Inventiva Sa (IVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Inventiva Sa stock (IVA) is currently trading at $6.02. Inventiva Sa PS ratio (Price-to-Sales) is 70.73. Analyst consensus price target for IVA is $15.88. WallStSmart rates IVA as Sell.
- IVA PE ratio analysis and historical PE chart
- IVA PS ratio (Price-to-Sales) history and trend
- IVA intrinsic value — DCF, Graham Number, EPV models
- IVA stock price prediction 2025 2026 2027 2028 2029 2030
- IVA fair value vs current price
- IVA insider transactions and insider buying
- Is IVA undervalued or overvalued?
- Inventiva Sa financial analysis — revenue, earnings, cash flow
- IVA Piotroski F-Score and Altman Z-Score
- IVA analyst price target and Smart Rating
Inventiva Sa
📊 No data available
Try selecting a different time range
Smart Analysis
Inventiva Sa (IVA) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Inventiva Sa (IVA) Key Strengths (1)
Revenue surging 105.20% year-over-year
Supporting Valuation Data
Inventiva Sa (IVA) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 70.7x annual revenue
Very low institutional interest at 5.18%
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Inventiva Sa (IVA) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 105.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (70.73), Price/Book (2.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1643.00%, Operating Margin at -992.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1643.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 105.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IVA's Price-to-Sales ratio of 70.73x trades at a deep discount to its historical average of 976.28x (43th percentile). The current valuation is 99% below its historical high of 6137.66x set in Oct 2021, and 360% above its historical low of 15.36x in Sep 2024. Over the past 12 months, the PS ratio has expanded from ~46.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Inventiva Sa (IVA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Inventiva Sa is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 17M with 105% growth year-over-year.
Key Findings
Revenue growing at 105% YoY, reaching 17M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 255% of revenue (43M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -54M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Inventiva Sa maintain 105%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Inventiva Sa.
Bottom Line
Inventiva Sa is a high-conviction growth story with revenue accelerating at 105% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:35:50 AM
About Inventiva Sa(IVA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.